ARTICLE | Product Development
Verve paves the way for in vivo base editors with trial start
Achieves base editing milestones with in vivo trial start and transition to prevalent indications
July 13, 2022 12:17 AM UTC
Verve dosed the first patient with an in vivo base editing therapy, marking a major milestone for the technology and positioning the biotech to leapfrog competitors that have focused first on ex vivo applications.
On Tuesday, Verve Therapeutics Inc. (NASDAQ:VERV) announced that a patient in New Zealand was dosed in a Phase Ib heart-1 study of VERVE-101 to treat heterozygous familial hypercholesterolemia...